Diabetes Insipidus and Concomitant Myocarditis: A Late Sequelae of COVID-19 Infection

Sheikh, Abu Baker; Javed, Nismat; Sheikh, Abdul Ahad Ehsan; Upadhyay, Shubhra; Shekhar, Rahul

doi:10.1177/2324709621999954

Cited by 33 publications

(30 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In this study involving 61survivors of SARS, 40% had evidence of central hypocortisolism and 5% had central hypothyroidism. To the best of our knowledge, there are only two published reports of COVID-19 infection-related CDI [ 3 , 4 ]. Like our patient, both these cases developed CDI 4–5 weeks after COVID-19 infection.…”

mentioning

confidence: 99%

Central diabetes insipidus (Infundibuloneuro hypophysitis): A late complication of COVID-19 infection

Misgar

Rasool

Wani

et al. 2021

J Endocrinol Invest

View full text Add to dashboard Cite

mentioning

confidence: 99%

Central diabetes insipidus (Infundibuloneuro hypophysitis): A late complication of COVID-19 infection

Misgar

Rasool

Wani

et al. 2021

J Endocrinol Invest

View full text Add to dashboard Cite

“…Post-COVID-19 cases of central diabetes insipidus have been described. It is believed to be the consequence of a direct or immune-mediated (neuro)hypophysitis [51] or due to hypoxic encephalopathy, especially among patients who experienced serious respiratory failure [52]. On the other hand, nephrogenic diabetes insipidus may be the consequence of sedation (i.e., sevoflurane) in critically ill patients who underwent endotracheal intubation [53].…”

Section: Hypothalamus and Pituitary Glandmentioning

confidence: 99%

COVID-19 and the Endocrine System: A Comprehensive Review on the Theme

Lisco

Tullio

Stragapede

et al. 2021

JCM

View full text Add to dashboard Cite

: Background and aim. The review aimed to summarize advances in the topic of endocrine diseases and coronavirus disease 2019 (COVID-19). Methods. Scientific and institutional websites and databases were searched and data were collected and organized, when plausible, to angle the discussion toward the following clinical issues. (1) Are patients with COVID-19 at higher risk of developing acute or late-onset endocrine diseases or dysfunction? (2) May the underlying endocrine diseases or dysfunctions be considered risk factors for poor prognosis once the infection has occurred? (3) Are there defined strategies to manage endocrine diseases despite pandemic-related constraints? Herein, the authors considered only relevant and more frequently observed endocrine diseases and disorders related to the hypothalamic-pituitary region, thyroid and parathyroid glands, calcium-phosphorus homeostasis and osteoporosis, adrenal glands, and gonads. Main. Data highlight the basis of some pathophysiological mechanisms and anatomical alterations of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)-induced endocrine dysfunctions. Some conditions, such as adrenal insufficiency and cortisol excess, may be risk factors of worse clinical progression once the infection has occurred. These at-risk populations may require adequate education to avoid the SARS-CoV-2 infection and adequately manage medical therapy during the pandemic, even in emergencies. Endocrine disease management underwent a palpable restraint, especially procedures requiring obligate access to healthcare facilities for diagnostic and therapeutic purposes. Strategies of clinical triage to prioritize medical consultations, laboratory, instrumental evaluations, and digital telehealth solutions should be implemented to better deal with this probably long-term situation.

show abstract

“…Many electrolyte imbalances have been described in patients with COVID-19, hyponatremia being the most frequent sodium abnormality. However, there have been also reports of idiopathic central DI during severe COVID-19 [ 122 ] or its recovery [ 123 ].…”

Section: Sars-cov-2 Infection In Patients With Hypopituitarismmentioning

confidence: 99%

COVID-19 and hypopituitarism

Frara

Loli

Allora

et al. 2021

Rev Endocr Metab Disord

View full text Add to dashboard Cite

Besides the pulmonary manifestations caused by severe acute respiratory syndrome (SARS) coronavirus 2 (SARS-CoV-2), an emerging endocrine phenotype, which can heavily impact on the severity of the syndrome, has been recently associated with coronavirus disease 2019 (COVID-19). Patients with pituitary diseases or the pituitary gland itself may also be involved in COVID-19 clinical presentation and/or severity, causing pituitary apoplexy. Moreover, hypopituitarism is frequently burdened by several metabolic complications, including arterial hypertension, hyperglycemia, obesity and vertebral fractures, which have all been associated with poor outcomes and increased mortality in patients infected by SARS-CoV-2. This review will discuss hypopituitarism as a condition that might have a bidirectional relationship with COVID-19 due to the frequent presence of metabolic comorbidities, to the direct or indirect pituitary damage or being per se a potential risk factor for COVID-19. Finally, we will address the current recommendations for the clinical management of vaccines in patients with hypopituitarism and adrenal insufficiency.

show abstract

Diabetes Insipidus and Concomitant Myocarditis: A Late Sequelae of COVID-19 Infection

Cited by 33 publications

References 9 publications

Central diabetes insipidus (Infundibuloneuro hypophysitis): A late complication of COVID-19 infection

Central diabetes insipidus (Infundibuloneuro hypophysitis): A late complication of COVID-19 infection

COVID-19 and the Endocrine System: A Comprehensive Review on the Theme

COVID-19 and hypopituitarism

Contact Info

Product

Resources

About